 Phase clinical pharmacologic study intraperitoneal cisplatin fluorouracil patients advanced intraabdominal cancer Fluorouracil cisplatin display therapeutic synergy preclinical models effective treatment number solid tumors IV drug IP favorable pharmacologic profile acceptable clinical toxicity phase feasibility toxicity combination IP chemotherapy agents patients malignancy peritoneal space cisplatin mixed lactated Ringer solution IP hours days Cohorts patients concentrations mmol/L mg mmol/L dose-limiting toxicity median granulocyte nadir cells microliter dose mmol/L Intrapatient escalation dose cycles chemotherapy concentrations mmol/L concentration mmol/L Other toxicities mild nausea cycles therapy cycles diarrhea cycles Abdominal pain renal dysfunction peripheral neuropathy oral mucositis dose Peritoneal fluid plasma concentrations high-performance liquid chromatography HPLC patients Mean peak plasma concentrations mumol/L mumol/L peritoneal fluid area curve AUC ratios Nine patients nonbulky disease resolution malignant ascites reduction peritoneal studding tumor repeat laparotomy combination IP chemotherapy cisplatin feasible acceptable clinical toxicity favorable pharmacologic profile recommended dose phase II trials mg mixed cisplatin isotonic fluid